Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Net Cash Flow (2016 - 2025)

Integra Lifesciences Holdings' Net Cash Flow history spans 17 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 96.82% year-over-year to $1.3 million; the TTM value through Dec 2025 reached -$29.3 million, down 24.53%, while the annual FY2025 figure was -$29.3 million, 24.53% down from the prior year.
  • Net Cash Flow for Q4 2025 was $1.3 million at Integra Lifesciences Holdings, down from $15.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $320.5 million in Q1 2024 and bottomed at -$375.5 million in Q2 2024.
  • The 5-year median for Net Cash Flow is -$6.6 million (2023), against an average of -$11.5 million.
  • The largest YoY upside for Net Cash Flow was 832.74% in 2024 against a maximum downside of 18527.13% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $42.3 million in 2021, then plummeted by 258.78% to -$67.2 million in 2022, then soared by 92.01% to -$5.4 million in 2023, then soared by 832.74% to $39.3 million in 2024, then tumbled by 96.82% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Net Cash Flow are $1.3 million (Q4 2025), $15.1 million (Q3 2025), and -$33.9 million (Q2 2025).